Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RF ablation · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Treatment |
| Name | Type | Description |
|---|---|---|
| RF ablation (Rita Medical Systems Model 1500x) | DEVICE | computed tomography-guided RF ablation with an expandable electrode needle |
Inclusion Criteria: 1. adult (\> 18 years) male or female patient 2. patient has biopsy-proven NSCLC or lung metastasis 3. patient has been rejected for surgery and has been considered unfit for radiation therapy or chemotherapy 4. patient has as many as 3 tumors per lung, each 3.5 cm or smaller in...
Top 20 of 90 competitors
RF ablation is a minimally invasive procedure being studied for the treatment of Non Small Cell Lung Cancer and pulmonary metastases. It uses radiofrequency energy to heat and destroy tumor tissue. The procedure is currently under clinical investigation and is not yet approved for this indication.
RF ablation is developed by AngioDynamics, Inc., a company traded on the NASDAQ under the ticker ANGO. The company is conducting clinical research to evaluate the procedure's effectiveness in treating Non Small Cell Lung Cancer and pulmonary metastases.
RF ablation is in Phase 2 clinical development for Non Small Cell Lung Cancer and pulmonary metastases. It is an investigational procedure and has not yet received regulatory approval. One Phase 2 trial has been completed to evaluate its safety and efficacy.
RF ablation was evaluated in a completed Phase 2 clinical trial with the identifier NCT00690703, titled 'Radiofrequency Ablation of Pulmonary Tumors Response Evaluation.' The trial enrolled 106 participants with Non Small Cell Lung Cancer and pulmonary metastases across the United States, Australia, Germany, Italy, and the United Kingdom.
RF ablation is not FDA approved for the treatment of Non Small Cell Lung Cancer or pulmonary metastases. It is an investigational procedure currently in clinical development. A Phase 2 trial has been completed, but the procedure remains under study and has not been cleared for this specific use.